Frank Kayser

Frank Kayser has extensive work experience in the field of small molecule drug discovery. Frank is currently the VP of Drug Discovery at Nitrase Therapeutics since June 2022. Prior to that, they served as the Senior VP of Drug Discovery at BioArdis from September 2018 to June 2022. From May 2016 to September 2018, they held the position of Senior VP of Chemistry, Integrated Programs at BioDuro.

In 2014, Frank founded their own company called Kayser Consulting, LLC., where they served as the Principal. The company provided expertise in small molecule drug discovery, including optimizing drug discovery strategies, evaluating portfolios and drug candidates, and assisting in the launch of companies and implementing research and drug discovery pipelines. Frank worked at Kayser Consulting until April 2016.

Before starting their own company, Frank was the Head of Chemistry at Nurix, Inc. from March 2012 to June 2014. Frank also held various positions at Amgen from August 2004 to December 2011, including Scientific Director. At Amgen, they successfully advanced multiple programs in different therapeutic areas and mentored medicinal chemistry teams.

Prior to joining Amgen, Frank worked at Tularik Inc. as a Sr. Principal Scientist. During their time there, they led chemistry efforts on multiple programs and played a key role in the development of the DGAT-1 project.

Frank's career in the field of small molecule drug discovery began at Merck Research Laboratories, where they worked as a Research Fellow and later as a Sr. Research Chemist. Frank contributed to the design and synthesis of small molecule therapeutics, particularly in the field of immunology.

Overall, Frank Kayser's work experience demonstrates their expertise and accomplishments in small molecule drug discovery and leadership roles within the pharmaceutical industry.

Frank Kayser completed their Ph.D. in Chemistry at The Philipp University of Marburg from 1983 to 1991. Afterward, they pursued postdoctoral work in Chemistry at UC Santa Barbara from 1992 to 1994, specifically under the supervision of B.H. Lipshutz.